Your cheat sheet on Gilead’s coronavirus drug
Just about any day now, we’re going to get our first glimpse at pivotal data on remdesivir, Gilead Sciences’ potential treatment for the novel coronavirus. It’s not hyperbolic to say the results — good, bad, or confusing — will be global news, so we figured we’d put together a need-to-know guide to the drug.
The basic gist is that, sometime this month, scientists in China will share results from a pair of clinical trials testing Gilead’s drug in patients who have either severe or moderate cases of Covid-19. The goal is to significantly beat placebo at improving symptoms within 28 days, scoring outcomes on a six-point scale.
But there’s a lot of nuance when it comes to interpreting the eventual results. For one, we still don’t know which patients are the best candidates for remdesivir, so it’s entirely possible that the study in severe patients will look underwhelming but not damage the case for Gilead’s drug in those with milder disease.
Here’s a lot more on what to look out for.
The basic gist is that, sometime this month, scientists in China will share results from a pair of clinical trials testing Gilead’s drug in patients who have either severe or moderate cases of Covid-19. The goal is to significantly beat placebo at improving symptoms within 28 days, scoring outcomes on a six-point scale.
But there’s a lot of nuance when it comes to interpreting the eventual results. For one, we still don’t know which patients are the best candidates for remdesivir, so it’s entirely possible that the study in severe patients will look underwhelming but not damage the case for Gilead’s drug in those with milder disease.
Here’s a lot more on what to look out for.
.png)
No hay comentarios:
Publicar un comentario